Article Text

other Versions

Outcomes of Treatment of Neovascular Glaucoma with Intravitreal Bevacizumab
  1. Alexei L Moraczewski (amoraczewski{at},
  2. Richard K Lee (rlee{at},
  3. Paul F Palmberg (ppalmberg{at},
  4. Philip J Rosenfeld (prosenfeld{at},
  5. William J Feuer (wfeuer{at}
  1. Bascom Palmer Eye Institute, United States
  2. Bascom Palmer Eye Institute, United States
  3. Bascom Palmer Eye Institute, United States
  4. Bascom Palmer Eye Institute, United States
  5. Bascom Palmer Eye Institute, United States


    Background/aims: To evaluate the course of treatment and outcomes of neovascular glaucoma (NVG) treated with intravitreal bevacizumab.

    Methods: The study is a retrospective, non-comparative, consecutive, interventional case series. Demographic data, past ocular history, cause of NVG, and anterior chamber angle status were recorded. Visual acuity (VA), intraocular pressure (IOP), number of IOP-lowering medications, and type of treatment administered were recorded at time of NVG diagnosis and at follow-up intervals. Treatment-related complications and reasons for vision loss were recorded.

    Results: The study included 56 eyes of 52 patients. At the time of NVG diagnosis, the median VA was count fingers and the mean IOP ± standard deviation was 40 ± 11 mm Hg. At 6 months after initial bevacizumab injection, the median VA was 1/200 and the mean IOP ± standard deviation was 18 ± 15 mm Hg. Seventy-one percent of eyes underwent panretinal photocoagulation after NVG diagnosis. Sixty-one percent of eyes received a glaucoma drainage implant (GDI). The Kaplan-Meier cumulative proportion of eyes with open angles receiving a GDI after initial bevacizumab injection was not statistically significantly different than that of eyes with closed angles. Forty-six percent of eyes received repeat bevacizumab injections. Eleven eyes had hyphema after both bevacizumab injection and GDI surgery, while 3 eyes had hyphema after GDI surgery but prior to initial bevacizumab injection.

    Conclusions: Intravitreal bevacizumab is now a frequently used adjunct for the treatment of NVG. Eyes must be monitored closely after initial injection of intravitreal bevacizumab, regardless of intial angle status, as many may still require surgery to lower IOP or repeat injections of intravitreal bevacizumab.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.